{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:44:27Z","timestamp":1778528667413,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03275-8","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:39:03Z","timestamp":1724420343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact on quality of life, health care access, and health care utilization of individuals with vitiligo: an analysis of the All of Us research program"],"prefix":"10.1007","volume":"316","author":[{"given":"Elliott","family":"Crummer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"6","key":"3275_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K (2020) Vitiligo: a review. Dermatology 236(6):571\u2013592. https:\/\/doi.org\/10.1159\/000506103","journal-title":"Dermatology"},{"issue":"2","key":"3275_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.det.2011.11.013","volume":"30","author":"SS Bhandarkar","year":"2012","unstructured":"Bhandarkar SS, Kundu RV (2012) Quality-of-life issues in Vitiligo. Dermatol Clin 30(2):255\u2013268. https:\/\/doi.org\/10.1016\/j.det.2011.11.013","journal-title":"Dermatol Clin"},{"key":"3275_CR3","unstructured":"FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older, U.S. Food & Drug Administration (2022) https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older. Accessed 1 February 2024"},{"issue":"6","key":"3275_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, Pandya AG (2021) Psychosocial effects of Vitiligo: a systematic literature review. Am J Clin Dermatol 22(6):757\u2013774. https:\/\/doi.org\/10.1007\/s40257-021-00631-6","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"3275_CR5","doi-asserted-by":"publisher","first-page":"e0241445","DOI":"10.1371\/journal.pone.0241445","volume":"15","author":"A Kussainova","year":"2020","unstructured":"Kussainova A, Kassym L, Akhmetova A, Glushkova N, Sabirov U, Adilgozhina S, Tuleutayeva R, Semenova Y (2020) Vitiligo and anxiety: a systematic review and meta-analysis. PLoS ONE 15(11):e0241445. https:\/\/doi.org\/10.1371\/journal.pone.0241445","journal-title":"PLoS ONE"},{"issue":"9","key":"3275_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.18129","volume":"36","author":"M Picardo","year":"2022","unstructured":"Picardo M, Huggins RH, Jones H, Marino R, Ogunsola M, Seneschal J (2022) The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J Eur Acad Dermatol Venereol 36(9):1507\u20131523. https:\/\/doi.org\/10.1111\/jdv.18129","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"3275_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.annder.2022.11.008","volume":"150","author":"MA Richard","year":"2023","unstructured":"Richard MA, Saint Aroman M, Baissac C, Merhand S, Aubert R, Audouze A, Legrand C, Beausillon C, Carre M, Raynal H, Bergqvist C, Taieb C, Cribier B (2023) Burden of visible [face and hands] skin diseases: results from a large international survey. Ann Dermatol Venereol 150(2):95\u2013100. https:\/\/doi.org\/10.1016\/j.annder.2022.11.008","journal-title":"Ann Dermatol Venereol"},{"issue":"9","key":"3275_CR8","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s13555-023-00983-3","volume":"13","author":"D Rosmarin","year":"2023","unstructured":"Rosmarin D, Soliman AM, Li C (2023) Real-world treatment patterns in patients with Vitiligo in the United States. Dermatol Ther (Heidelb) 13(9):2079\u20132091. https:\/\/doi.org\/10.1007\/s13555-023-00983-3","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"3275_CR9","first-page":"385","volume":"98","author":"T Chen","year":"2016","unstructured":"Chen T, Grau C, Suprun M, Silverberg NB (2016) Vitiligo patients experience barriers in accessing care. Cutis 98(6):385\u2013388","journal-title":"Cutis"},{"issue":"4","key":"3275_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2022.11.027","volume":"88","author":"F Ahmed","year":"2023","unstructured":"Ahmed F, Moseley I, Ragi SD, Ouellette S, Rao B (2023) Vitiligo in underrepresented communities: an all of us database analysis. J Am Acad Dermatol 88(4):945\u2013948. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.027","journal-title":"J Am Acad Dermatol"},{"key":"3275_CR11","unstructured":"Interactive Summary Health Statistics for Adults, Centers for Disease Control and Prevention (2022) https:\/\/wwwn.cdc.gov\/NHISDataQueryTool\/SHS_adult\/index.html. Accessed 1 February 2024"},{"key":"3275_CR12","unstructured":"Key Data on Health and Health Care by Race and Ethnicity, KFF (2023) https:\/\/www.kff.org\/racial-equity-and-health-policy\/report\/key-data-on-health-and-health-care-by-race-and-ethnicity\/. Accessed 1 February 2024"},{"key":"3275_CR13","unstructured":"All of Us Research Program Operational Protocol, All of Us (2021) https:\/\/allofus.nih.gov\/sites\/default\/files\/All%20of%20Us%20Research%20Program%20Operational%20Protocol%202022.pdf. Accessed 1 Feburary 2024"},{"key":"3275_CR14","unstructured":"2015 National Content Test (2024) Race and Ethnicity Analysis Report, United States Census Bureau https:\/\/www2.census.gov\/programs-surveys\/decennial\/2020\/program-management\/final-analysis-reports\/2015nct-race-ethnicity-analysis.pdf. Accessed 1"},{"issue":"5","key":"3275_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","volume":"143","author":"JH Lee","year":"2023","unstructured":"Lee JH, Ju HJ, Seo JM, Almurayshid A, Kim GM, Ezzedine K, Bae JM (2023) Comorbidities in patients with Vitiligo: a systematic review and Meta-analysis. J Invest Dermatol 143(5):777\u2013789e6. https:\/\/doi.org\/10.1016\/j.jid.2022.10.021","journal-title":"J Invest Dermatol"},{"issue":"9","key":"3275_CR16","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamadermatol.2023.2162","volume":"159","author":"N Mastacouris","year":"2023","unstructured":"Mastacouris N, Strunk A, Garg A (2023) Incidence and prevalence of diagnosed Vitiligo according to race and ethinicity, Age, and sex in the US. JAMA Dermatol 159(9):986\u2013990. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2162","journal-title":"JAMA Dermatol"},{"key":"3275_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08548-y","author":"P Finneran","year":"2023","unstructured":"Finneran P, Toribio MP, Natarajan P, Honigberg MC (2023) Delays in Accessing Healthcare across the Gender Spectrum in the all of Us Research Program. J Gen Intern Med. https:\/\/doi.org\/10.1007\/s11606-023-08548-y","journal-title":"J Gen Intern Med"},{"issue":"1","key":"3275_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","volume":"158","author":"K Gandhi","year":"2022","unstructured":"Gandhi K, Ezzedine K, Anastassopoulos KP, Patel R, Sikirica V, Daniel SR, Napatalung L, Yamaguchi Y, Baik R, Pandya AG (2022) Prevalence of Vitiligo among adults in the United States. JAMA Dermatology 158(1):43\u201350. https:\/\/doi.org\/10.1001\/jamadermatol.2021.4724","journal-title":"JAMA Dermatology"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03275-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03275-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03275-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:08:18Z","timestamp":1729699698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03275-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3275"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03275-8","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Rosmarin has consulted, spoken for, or conducted trials for the following companies: AbbVie, Abcuro, Almirall, AltruBio, Amgen, Arena, Astria, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Galderma, Incyte, Janssen, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, VielaBio, Zura Bio; Joshua T. Cohen has consulted or received grant support from the following life sciences companies and groups: Abbvie, Amgen, Analysis Group, Astra Zeneca, Biogen, Brystol Myers Squibb, Eli Lily, Giliead, IQvia, Johnson and Johnson, Lundbeck, Merck, Moderna, National Pharmaceutical Council, No Patient Left Behind, Novartis, Partnership for Health Analytic Research, Patient Square Capital, Pfizer, Pharmerit, PhRMA Foundation, Precision Health Economics, RA Capital, Regeneron, Sage, Sanofi, Sarepta, Vir Bio; Elliott Crummer and Pei-Jung Lin have no relevant competing interests to declare. IRB Approval Status. This study (STUDY00003692) has been deemed not to be human subjects research by the Tufts Health Sciences Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"554"}}